Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capac ...

A month has gone by since the last earnings report for Qiagen (QGEN) . Shares have added about 1.6% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. QIAGEN Q1 Earnings and Revenues Top, Margins Rise QIAGEN N.V ...

In the first quarter of 2024, the Genomics/NGS group reported higher sales of universal library prep kits for use with third-party next-generation sequencers. The QDI business continued to see solid demand trends, setting out an optimistic CER growth outlook for the full year. Furthermore, QIAGEN continuously integrates AI technology into the QDI portfolio, launching an AI-driven knowledge base for drug discovery and enhancing QCI Interpret software for rare disease gene coverage. Strategic Collaborations t ...

QIAGEN N.V. (QGEN) recently announced the receipt of the European Union (EU) Technical Documentation Assessment and Quality Management System certificate under the European In Vitro Diagnostic Medical Device Regulation for its updated version of its clinical decision support platform — QIAGEN Clinical Insight (QCI) Interpret. The recent regulatory approval ensures greater patient protection, transparency of information and traceability of data. For investors' note, QCI Interpret is a software that aids in i ...

QIAGEN N.V. (QGEN) recently secured FDA clearance for the QIAstat-Dx Respiratory Panel Plus syndromic test. Previously authorized under the FDA Emergency Use Authorization (“EUA”) as the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the test is designed to support clinical decision-making in diagnosing upper respiratory infections and covers 21 viral and bacterial targets.The latest development will strongly boost the company’s Molecular Diagnostics business.Significance of the QIAstat-Dx Respiratory Panel PlusR ...

QIAGEN N.V. (QGEN) recently entered into a cooperative research and development agreement (CRADA) with the Federal Bureau of Investigation (FBI). The deal advances a novel test for its QIAcuity digital PCR devices that will enhance forensics by improving the quantification of DNA in human samples. The recent development will strengthen QIAGEN's leading position in the human identification (HID) and forensics business. More on the News As a federally accredited laboratory, the FBI performs research and devel ...

Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. The QIAstat-Dx Respiratory Panel Plus is designed to support clinical decision-making in diagnosing upper respiratory infections and covers 21 viral and bacterial targets. It was previously authorized under a U.S. FDA Emergency ...

Have you evaluated the performance of Qiagen's (QGEN) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this diagnostic products maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth j ...

Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended March 31, 2024 Table of Contents Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2 2023 Condensed Consolidated Statements of Income (unaudited) for the three months ended 4 March 31, 2024 and 2023 Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three months 5 ended March 31, 2024 and 2023 Condensed Consolid ...

Your contacts Coordinator Investor Relations | --- | --- | |--------------------------------------|---------------| | Analyst and Investor Day (New York) | June 17, 2024 | | Annual General Meeting | June 21, 2024 | | Q2 2024 results | July 2024 | Internet: corporate.QIAGEN.com www.x.com/QIAGEN | --- | --- | --- | |---------------------------------------------------------------|-------------------|-------------------| | Three months ended (In $ thousands) | March 31, 2024 | March 31, 2023 | | Cash flows from ...